Healthcare - Eli Lilly and Company and Neuroaxis, Romania's first integrated neurology and neuroimaging clinic, now part of the Regina Maria Network, have launched a

Eli Lilly and Company inició la construcción de una instalación de $6.5 mil millones en Houston y anunció una contribución de $15 millones a San Jacinto College.

Encouraging updates from Eli Lilly CEO Dave Ricks strengthen the bull case for the stock.

Eli Lilly (LLY) closed at $1 in the latest trading session, marking a +1.04% move from the prior day.

Eli Lilly received full U.S. FDA approval for Inluriyo, an oral estrogen receptor antagonist, in combination with Verzenio for adults with ER+, HER2–, ESR1-mutated locally advanced or metastatic breast cancer whose disease progressed after at least one line of endocrine therapy, based on Phase 3 EMBER-3 data. The new all-oral regimen targets two key drivers of ER+ breast cancer while maintaining an established tolerability profile, which reinforces Eli Lilly's focus on broadening oncology...

Eli Lilly CEO touts Foundayo oral GLP-1 growth abroad, rising Rx share and Medicare uptake. Read more here.

They're the latest metrics on how much the new Medicare coverage is expanding access to GLP-1 medicines since it launched in July.

The top healthcare stock has been underperforming the market, and its returns haven

CEO Dave Ricks also broke ground Monday on a $6.5 billion manufacturing plant in Houston that Lilly expects will be operational by 2030

Eli Lilly is trying to catch up in the GLP-1 pill market to Novo, which got a head start in the space.